Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CO-LAV vs CEPHULAC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CO-LAV is a combination of codeine and acetylsalicylic acid (aspirin). Codeine is a prodrug that is metabolized to morphine, which acts as an agonist at mu-opioid receptors, producing analgesia. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and providing analgesic, antipyretic, and anti-inflammatory effects.
Lactulose, a synthetic disaccharide, is not absorbed from the gastrointestinal tract. It is metabolized by colonic bacteria to form short-chain fatty acids (e.g., lactic, acetic, formic acids), which acidify the colonic contents. In hepatic encephalopathy, the acidic environment converts ammonia (NH3) to ammonium (NH4+), which is poorly absorbed and excreted in feces. Additionally, the osmotic effect of lactulose draws water into the colon, softening stools and increasing bowel movements.
mild to moderate pain,fever,inflammation
Treatment of constipation,Hepatic encephalopathy (portal-systemic encephalopathy) including the prevention and treatment of coma
Adults: 1 tablet (trimethoprim 80 mg/sulfamethoxazole 400 mg) orally twice daily for 5-7 days; for Pneumocystis jirovecii pneumonia, 2 tablets (160 mg/800 mg) orally every 6 hours for 21 days.
30-45 m L (6.67-10 g lactulose) orally 3-4 times daily for constipation; for hepatic encephalopathy, 30-45 m L orally 3-4 times daily titrated to produce 2-3 soft stools per day, or 300 m L in 700 m L of water or saline as retention enema for 30-60 min every 4-6 hours.
Unknown
Terminal elimination half-life is 7-10 hours (renal impairment: prolonged); systemic absorption is minimal (<3%) after oral administration, so half-life reflects clearance of absorbed fraction.
Codeine is metabolized via CYP2D6 to morphine (active), and via CYP3A4 to norcodeine, with further glucuronidation. Aspirin is rapidly hydrolyzed to salicylate by esterases in the gastrointestinal tract and liver; salicylate is primarily metabolized by conjugation with glycine (salicyluric acid) and glucuronic acid, with minor oxidation.
Not absorbed; metabolized by colonic bacteria (e.g., Lactobacillus, Bacteroides) to low molecular weight organic acids.
CO-LAV is not a recognized drug. Please check the drug name.
Primarily renal (20-30% as unchanged drug) and fecal (up to 70% as unmetabolized drug via biliary elimination; following gastric acid-mediated degradation, only 5-10% reaches urine as intact lactulose; hepatic metabolism is negligible).
Unknown
Negligible (<5%): lactulose does not bind significantly to albumin or other plasma proteins due to its hydrophilic nature.
Unknown
0.5-1.0 L/kg (estimated from systemic absorption studies; limited data due to minimal absorption; reflects distribution largely into extracellular water).
Unknown
Oral: <3% (due to poor absorption and extensive metabolism by colonic bacteria; most of the drug remains in the gut lumen). Rectal: similar to oral, as systemic absorption is minimal.
GFR 15-30 m L/min: administer 50% of standard dose every 12 hours; GFR <15 m L/min: contraindicated (except during hemodialysis, where 50% dose post-dialysis may be used).
No dose adjustment required for renal impairment as lactulose is minimally absorbed and primarily acts locally in the colon.
Child-Pugh Class A/B: no adjustment necessary; Child-Pugh Class C: contraindicated due to risk of severe hepatotoxicity.
Not specifically adjusted based on Child-Pugh score; dose is titrated to achieve desired stool frequency; caution in severe hepatic impairment due to risk of electrolyte disturbances.
Children >2 months: 8 mg/kg/day (based on trimethoprim) in two divided doses for UTI; for PCP prophylaxis: 150 mg/m²/day in two divided doses on 3 consecutive days per week.
Infants: 2.5-10 m L/day in divided doses; older children: 10-25 m L/day; adolescents: 15-30 m L/day; all for constipation; for hepatic encephalopathy, doses as low as 5-10 m L 3-4 times daily with dose adjusted to produce 2-3 soft stools per day.
Increased risk of severe adverse reactions (e.g., hyperkalemia, renal impairment); monitor renal function and potassium levels; initiate at lower doses (e.g., half the standard dose) and titrate cautiously.
Initiate at lower end of dosing range (15-30 m L/day) due to increased risk of dehydration and electrolyte imbalance; monitor for diarrhea and adjust accordingly.
Codeine is contraindicated in children younger than 12 years and in children younger than 18 years following tonsillectomy and/or adenoidectomy due to risk of respiratory depression and death associated with ultra-rapid metabolism of codeine to morphine. Aspirin is associated with Reye's syndrome in children and adolescents with viral illnesses.
None
Respiratory depression, risk of opioid addiction, abuse, and misuse; life-threatening respiratory depression in children with CYP2D6 ultra-rapid metabolizers; Reye's syndrome in children and adolescents with viral illnesses; increased risk of bleeding; gastrointestinal perforation and bleeding; renal impairment; hypersensitivity reactions including anaphylaxis and aspirin-sensitive asthma; drug interactions with CYP2D6 and CYP3A4 inhibitors/inducers; use in pregnancy and lactation.
Electrolyte imbalance with prolonged use, especially in debilitated patients,Diarrhea may cause fluid and electrolyte loss,Galactose intolerance (contraindicated in patients requiring low galactose diet due to lactose content in some preparations),Monitor serum electrolytes in patients receiving high doses for hepatic encephalopathy
Hypersensitivity to codeine, aspirin, or NSAIDs; children younger than 12 years; children younger than 18 years following tonsillectomy and/or adenoidectomy; significant respiratory depression; acute or severe bronchial asthma; paralytic ileus; bleeding disorders; concomitant use with MAOIs or within 14 days; third trimester of pregnancy; nursing mothers (due to aspirin); viral illness with fever in children and adolescents (risk of Reye's syndrome); concomitant use with anticoagulants (e.g., warfarin) due to bleeding risk.
Patients requiring a low-galactose diet (lactulose contains galactose and lactose),Intestinal obstruction,Suspected gastrointestinal obstruction or perforation
Grapefruit juice may increase colchicine levels due to CYP3A4 inhibition; avoid concurrent consumption. High-fat meals may reduce colchicine absorption? No data for colchicine specifically; take with or without food. Alcohol may worsen gout symptoms and increase risk of pancreatitis; avoid. Lactulose effect is not dependent on food; can be taken with or without meals.
No specific food interactions. Avoid concurrent use with other laxatives unless directed. High-fiber foods may enhance effect; ensure adequate fluid intake.
First trimester: Not associated with major congenital malformations based on limited human data. Second and third trimesters: No specific fetal risks reported; however, placental transfer is minimal.
Lactulose (CEPHULAC) is not absorbed systemically; therefore, fetal exposure is negligible. Animal studies have not shown teratogenic effects. In clinical practice, no fetal risks have been identified in any trimester.
Considered compatible with breastfeeding. M/P ratio unknown; limited excretion into breast milk expected due to high protein binding and low oral bioavailability.
Lactulose is not excreted into breast milk due to minimal systemic absorption. It is considered compatible with breastfeeding. M/P ratio: Not applicable (negligible absorption).
No dose adjustment required for pregnancy. Pharmacokinetics are not significantly altered in pregnancy; standard dosing recommended.
No dose adjustment required. Pharmacokinetics are unchanged in pregnancy due to lack of systemic absorption. Standard dosing of 15-30 m L (10-20 g) once daily, up to 60 m L/day in divided doses, is appropriate.
CO-LAV (colchicine/lactulose) is a fixed-dose combination used for gout flare prophylaxis but poses risks in renal impairment; colchicine dose must be reduced in CKD stage 4-5 due to narrow therapeutic index. Lactulose may cause bloating and flatulence; monitor for diarrhea-related electrolyte disturbances. Avoid concurrent use with strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) and P-glycoprotein inhibitors (e.g., cyclosporine) to prevent colchicine toxicity. In liver impairment, colchicine accumulation can occur; use with caution. Geriatric patients are more susceptible to colchicine neurotoxicity and myopathy.
Cephulac (lactulose) is a non-absorbable disaccharide used for constipation and hepatic encephalopathy. In hepatic encephalopathy, titrate to produce 2-3 soft stools per day. Monitor serum electrolytes, especially in elderly or renal impairment. Onset of action for constipation may be 24-48 hours. Do not confuse with other lactose-containing products.
Take this medication exactly as prescribed; do not exceed the recommended dose of colchicine.,If you have kidney or liver disease, inform your doctor; dose adjustments may be needed.,Report any signs of colchicine toxicity: muscle pain, weakness, numbness, tingling, or unusual bruising/bleeding.,Lactulose may cause gas, bloating, or stomach cramps; these usually improve over time.,Stay well hydrated to prevent diarrhea-related dehydration.,Do not take any other medications, including over-the-counter, without consulting your doctor.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss risks with your healthcare provider.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; may take 24-48 hours to produce a bowel movement.,For hepatic encephalopathy, maintain 2-3 soft stools daily; do not skip doses.,May cause bloating, gas, or cramping initially; usually resolves.,Do not take other laxatives without consulting your doctor.,Report severe diarrhea, vomiting, or muscle cramps to your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CO-LAV vs CEPHULAC, answered by our medical review team.
CO-LAV is a Laxative/Bowel Evacuant that works by CO-LAV is a combination of codeine and acetylsalicylic acid (aspirin). Codeine is a prodrug that is metabolized to morphine, which acts as an agonist at mu-opioid receptors, producing analgesia. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and providing analgesic, antipyretic, and anti-inflammatory effects.. CEPHULAC is a Laxative that works by Lactulose, a synthetic disaccharide, is not absorbed from the gastrointestinal tract. It is metabolized by colonic bacteria to form short-chain fatty acids (e.g., lactic, acetic, formic acids), which acidify the colonic contents. In hepatic encephalopathy, the acidic environment converts ammonia (NH3) to ammonium (NH4+), which is poorly absorbed and excreted in feces. Additionally, the osmotic effect of lactulose draws water into the colon, softening stools and increasing bowel movements.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CO-LAV and CEPHULAC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CO-LAV is: Adults: 1 tablet (trimethoprim 80 mg/sulfamethoxazole 400 mg) orally twice daily for 5-7 days; for Pneumocystis jirovecii pneumonia, 2 tablets (160 mg/800 mg) orally every 6 hours for 21 days.. The standard adult dose of CEPHULAC is: 30-45 m L (6.67-10 g lactulose) orally 3-4 times daily for constipation; for hepatic encephalopathy, 30-45 m L orally 3-4 times daily titrated to produce 2-3 soft stools per day, or 300 m L in 700 m L of water or saline as retention enema for 30-60 min every 4-6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CO-LAV and CEPHULAC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CO-LAV is classified as Category C. First trimester: Not associated with major congenital malformations based on limited human data. Second and third trimesters: No specific fetal risks reported; however, placental t. CEPHULAC is classified as Category C. Lactulose (CEPHULAC) is not absorbed systemically; therefore, fetal exposure is negligible. Animal studies have not shown teratogenic effects. In clinical practice, no fetal risks . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.